The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma

Abstract Background This study aims to construct radiomics models based on [18F]FDG PET/CT using multiple machine learning methods to predict the EGFR mutation status of lung adenocarcinoma and evaluate whether incorporating clinical parameters can improve the performance of radiomics models. Method...

Full description

Bibliographic Details
Main Authors: Jianxiong Gao, Rong Niu, Yunmei Shi, Xiaoliang Shao, Zhenxing Jiang, Xinyu Ge, Yuetao Wang, Xiaonan Shao
Format: Article
Language:English
Published: SpringerOpen 2023-04-01
Series:EJNMMI Research
Subjects:
Online Access:https://doi.org/10.1186/s13550-023-00977-4
_version_ 1797849870217773056
author Jianxiong Gao
Rong Niu
Yunmei Shi
Xiaoliang Shao
Zhenxing Jiang
Xinyu Ge
Yuetao Wang
Xiaonan Shao
author_facet Jianxiong Gao
Rong Niu
Yunmei Shi
Xiaoliang Shao
Zhenxing Jiang
Xinyu Ge
Yuetao Wang
Xiaonan Shao
author_sort Jianxiong Gao
collection DOAJ
description Abstract Background This study aims to construct radiomics models based on [18F]FDG PET/CT using multiple machine learning methods to predict the EGFR mutation status of lung adenocarcinoma and evaluate whether incorporating clinical parameters can improve the performance of radiomics models. Methods A total of 515 patients were retrospectively collected and divided into a training set (n = 404) and an independent testing set (n = 111) according to their examination time. After semi-automatic segmentation of PET/CT images, the radiomics features were extracted, and the best feature sets of CT, PET, and PET/CT modalities were screened out. Nine radiomics models were constructed using logistic regression (LR), random forest (RF), and support vector machine (SVM) methods. According to the performance in the testing set, the best model of the three modalities was kept, and its radiomics score (Rad-score) was calculated. Furthermore, combined with the valuable clinical parameters (gender, smoking history, nodule type, CEA, SCC-Ag), a joint radiomics model was built. Results Compared with LR and SVM, the RF Rad-score showed the best performance among the three radiomics models of CT, PET, and PET/CT (training and testing sets AUC: 0.688, 0.666, and 0.698 vs. 0.726, 0.678, and 0.704). Among the three joint models, the PET/CT joint model performed the best (training and testing sets AUC: 0.760 vs. 0.730). The further stratified analysis found that CT_RF had the best prediction effect for stage I–II lesions (training set and testing set AUC: 0.791 vs. 0.797), while PET/CT joint model had the best prediction effect for stage III–IV lesions (training and testing sets AUC: 0.722 vs. 0.723). Conclusions Combining with clinical parameters can improve the predictive performance of PET/CT radiomics model, especially for patients with advanced lung adenocarcinoma.
first_indexed 2024-04-09T18:52:13Z
format Article
id doaj.art-ee5fd8fcadd34e44bb00b448a673af17
institution Directory Open Access Journal
issn 2191-219X
language English
last_indexed 2024-04-09T18:52:13Z
publishDate 2023-04-01
publisher SpringerOpen
record_format Article
series EJNMMI Research
spelling doaj.art-ee5fd8fcadd34e44bb00b448a673af172023-04-09T11:26:44ZengSpringerOpenEJNMMI Research2191-219X2023-04-0113111310.1186/s13550-023-00977-4The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinomaJianxiong Gao0Rong Niu1Yunmei Shi2Xiaoliang Shao3Zhenxing Jiang4Xinyu Ge5Yuetao Wang6Xiaonan Shao7Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow UniversityDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow UniversityDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow UniversityDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow UniversityDepartment of Radiology, The Third Affiliated Hospital of Soochow UniversityDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow UniversityDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow UniversityDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow UniversityAbstract Background This study aims to construct radiomics models based on [18F]FDG PET/CT using multiple machine learning methods to predict the EGFR mutation status of lung adenocarcinoma and evaluate whether incorporating clinical parameters can improve the performance of radiomics models. Methods A total of 515 patients were retrospectively collected and divided into a training set (n = 404) and an independent testing set (n = 111) according to their examination time. After semi-automatic segmentation of PET/CT images, the radiomics features were extracted, and the best feature sets of CT, PET, and PET/CT modalities were screened out. Nine radiomics models were constructed using logistic regression (LR), random forest (RF), and support vector machine (SVM) methods. According to the performance in the testing set, the best model of the three modalities was kept, and its radiomics score (Rad-score) was calculated. Furthermore, combined with the valuable clinical parameters (gender, smoking history, nodule type, CEA, SCC-Ag), a joint radiomics model was built. Results Compared with LR and SVM, the RF Rad-score showed the best performance among the three radiomics models of CT, PET, and PET/CT (training and testing sets AUC: 0.688, 0.666, and 0.698 vs. 0.726, 0.678, and 0.704). Among the three joint models, the PET/CT joint model performed the best (training and testing sets AUC: 0.760 vs. 0.730). The further stratified analysis found that CT_RF had the best prediction effect for stage I–II lesions (training set and testing set AUC: 0.791 vs. 0.797), while PET/CT joint model had the best prediction effect for stage III–IV lesions (training and testing sets AUC: 0.722 vs. 0.723). Conclusions Combining with clinical parameters can improve the predictive performance of PET/CT radiomics model, especially for patients with advanced lung adenocarcinoma.https://doi.org/10.1186/s13550-023-00977-4lung adenocarcinoma[18F]FDG PET/CTRadiomicsEpidermal growth factor receptorPrediction
spellingShingle Jianxiong Gao
Rong Niu
Yunmei Shi
Xiaoliang Shao
Zhenxing Jiang
Xinyu Ge
Yuetao Wang
Xiaonan Shao
The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma
EJNMMI Research
lung adenocarcinoma
[18F]FDG PET/CT
Radiomics
Epidermal growth factor receptor
Prediction
title The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma
title_full The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma
title_fullStr The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma
title_full_unstemmed The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma
title_short The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma
title_sort predictive value of 18f fdg pet ct radiomics combined with clinical features for egfr mutation status in different clinical staging of lung adenocarcinoma
topic lung adenocarcinoma
[18F]FDG PET/CT
Radiomics
Epidermal growth factor receptor
Prediction
url https://doi.org/10.1186/s13550-023-00977-4
work_keys_str_mv AT jianxionggao thepredictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT rongniu thepredictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT yunmeishi thepredictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT xiaoliangshao thepredictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT zhenxingjiang thepredictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT xinyuge thepredictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT yuetaowang thepredictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT xiaonanshao thepredictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT jianxionggao predictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT rongniu predictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT yunmeishi predictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT xiaoliangshao predictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT zhenxingjiang predictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT xinyuge predictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT yuetaowang predictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma
AT xiaonanshao predictivevalueof18ffdgpetctradiomicscombinedwithclinicalfeaturesforegfrmutationstatusindifferentclinicalstagingoflungadenocarcinoma